Immunotherapy for vulvar carcinoma with virus-modified homologous extracts

Ralph S. Freedman, James M. Bowen, Jay H. Herson, J. Taylor Wharton, Creighton L. Edwards, Felix N. Rutledge

Research output: Contribution to journalArticlepeer-review


A membrane-enriched extract of a virus-infected vulvar carcinoma cell line was evaluated as adjunctive immunotherapy in 16 patients who had vulvar carcinoma with lymph node metastases. Thirteen patients also received adjunctive radiation therapy based on individually assessed risk factors. Two patients developed progressive disease. The median disease-free survival for the group was 26 + months, as compared with nine months for a historical group that had undergone surgery alone and 16 months for a second group that had received surgery and adjunctive radiation therapy. The median disease-free survival of the immunotherapy group was longer than that of either of the two historical groups. Over 400 doses of extract, each equivalent to 1.5 mg protein, were administered without significant side effects. Evidence is presented for humoral and cellular augmented immune reactivity. The authors suggest that this approach be evaluated further to determine its efficacy in preventing recurrence in selected high-risk patients who have vulvar carcinoma.

Original languageEnglish (US)
Pages (from-to)707-714
Number of pages8
JournalObstetrics and gynecology
Issue number6
StatePublished - Dec 1983
Externally publishedYes

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Immunotherapy for vulvar carcinoma with virus-modified homologous extracts'. Together they form a unique fingerprint.

Cite this